Abstract: An apparatus and a method for controlling a velocity of an autonomous driving vehicle is provided. The method includes steps of: obtaining information of an environment surrounding the vehicle when an obstacle is detected to be on a planning path of the vehicle; obtaining an initial reference velocity profile of the vehicle; determining a safety factor based on the initial reference velocity profile, the information of the environment and information of the vehicle, wherein the safety factor at least comprises a safety distance between the vehicle and the obstacle for the vehicle to follow the obstacle; determining an optimized reference velocity profile based on the information of the environment, the information of the vehicle and the safety factor; and performing the step of determining the safety factor by using the optimized reference velocity profile as the initial reference velocity profile and the step of determining the optimized reference velocity iteratively.

Abstract: A side supporting type vehicle roof tent comprises a tent rack and a tent cloth fitted inside the tent rack. The tent rack comprises a base, a top cover, and at least one support connecting rod; the rear end of the top cover is pivotally connected to the rear end of the base; the support connecting rod is provided between the base and the top cover; one end of the support connecting rod is connected to the top cover, and the other end is connected to the base; the tent cloth is provided between the top cover and the base in a matching manner; the tent cloth between the front end of the top cover and the front end of the base is provided with an opening. The tent is simple in structure and easy to unfold or fold.

Abstract: In one aspect, the present invention provides a fiber reinforced metal composite comprising a metal layer and a fiber layer which are arranged in a stack, and adjacent layers are fixed by bonding; the composite has a two-layered or three-layered structure, wherein one layer is closely adhered to another layer and the thickness of the layer is from 0.6 mm˜0.9 mm. Such structure changes the structure of the existing fiber metal composite characterized by generally having more than three layers, and greatly reduces the thickness of the composite while maintaining good mechanical properties. In another aspect, the present invention discloses an application of fiber reinforced metal composite in the field of luggage case manufacturing, provides two preparation methods for providing fiber reinforced metal case shell with simple and available operations.

Abstract: Example embodiments include methods of treating a surface of an aluminum (Al) alloy or magnesium (Mg) with an electrolyte to obtain a surface with a coloration that is uniformly enhanced. Example embodiments also include surface-treated Al alloy or Mg alloy made by the example methods.

Abstract: A method for generating a road map for vehicle navigation comprises: providing original road image data having an image of a road; identifying boundary lines defining respective lane segments of the road from the original road image data; associating traffic properties with the lane segments defined by the boundary lines, respectively; grouping the lane segments to generate road segments; and combining the road segments with traffic control objects corresponding thereto so as to generate the road map for vehicle navigation.

Abstract: The present invention provides a coating composition and a method of imparting self-healing, anti-microbial and anti-fouling properties onto a substrate at ambient temperature without external intervention. The coating composition comprises a product of an in-situ polymerization mixture comprising diisocyanate, polyol and saccharide. The polyol is a polyester or a polyether.

Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

Abstract: Example embodiments include methods of treating a surface of an aluminum (Al) alloy or magnesium (Mg) with an electrolyte to obtain a surface with a coloration that is uniformly enhanced. Example embodiments also include surface-treated Al alloy or Mg alloy made by the example methods.

Abstract: Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2 -dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments.

Abstract: Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments.

Abstract: The present invention includes a flat face, a dots raising mechanism, a display cell, a first column, a second column, an interface, and a connection port. The first column includes a first dot, second dot, and a third dot while the second column includes a fourth dot, a fifth dot, and a sixth dot. The columns are on the display cell. The display cell is capable of displaying a single Braille character. To convey information from a text source, the display cell raises and lowers the dots, successively forming different characters. A first time interval, a second time interval, and a third time interval help differentiate the first column from the second column, a first character from a following character, and a first word from a following word. The time intervals simulate physical space between and with the cells found in printed Braille.

Abstract: 3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.

Abstract: A method and apparatus for processing mobile-IP registration messages. Upon receipt of a mobile-IP registration request (RRQ) message that designates a care-of address matching the mobile-IP home agent's IP address, the RRQ would be dropped. Alternatively, before deciding to drop such an RRQ, the invention may further involve determining whether the home agent is currently functioning as a foreign agent for the requesting mobile node, which would justify the care-of address matching the home agent's IP address. If the home agent is not currently functioning as a foreign agent for the mobile node, then the RRQ would be dropped. On the other hand, if the home agent is currently functioning as a foreign agent for the mobile node, then RRQ processing would proceed as normal.

Abstract: 3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.